148 related articles for article (PubMed ID: 26174485)
1. Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.
Wellbrock C
EMBO Mol Med; 2015 Sep; 7(9):1087-9. PubMed ID: 26174485
[TBL] [Abstract][Full Text] [Related]
2. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.
Kemper K; Krijgsman O; Cornelissen-Steijger P; Shahrabi A; Weeber F; Song JY; Kuilman T; Vis DJ; Wessels LF; Voest EE; Schumacher TN; Blank CU; Adams DJ; Haanen JB; Peeper DS
EMBO Mol Med; 2015 Sep; 7(9):1104-18. PubMed ID: 26105199
[TBL] [Abstract][Full Text] [Related]
3. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
4. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse.
Tauber M; Pages C; La Selva R; Schneider P; Chardin J; Osio A; Mourah S; Culine S; Vercellino L; Bagot M; Lebbé C
Eur J Dermatol; 2013; 23(5):702-3. PubMed ID: 24135270
[No Abstract] [Full Text] [Related]
6. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib: the first drug approved for BRAF-mutant cancer.
Bollag G; Tsai J; Zhang J; Zhang C; Ibrahim P; Nolop K; Hirth P
Nat Rev Drug Discov; 2012 Nov; 11(11):873-86. PubMed ID: 23060265
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
9. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
10. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
11. Community experience of vemurafenib for BRAF(V600) melanoma.
Hersey P
Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
[No Abstract] [Full Text] [Related]
12. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
14. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
15. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
16. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
[No Abstract] [Full Text] [Related]
18. A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
LaPresto L; Cranmer L; Morrison L; Erickson CP; Curiel-Lewandrowski C
JAMA Dermatol; 2013 Mar; 149(3):279-81. PubMed ID: 23552479
[No Abstract] [Full Text] [Related]
19. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib.
Kolar GR; Miller-Thomas MM; Schmidt RE; Simpson JR; Rich KM; Linette GP
J Clin Oncol; 2013 Jan; 31(3):e40-3. PubMed ID: 23233711
[No Abstract] [Full Text] [Related]
20. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
